Clinical trials: Hematological Malignancies
Childhood Acute Lymphoblastic Leukemia in Remission, Childhood Acute Myeloid Leukemia in Remission
Donor Bone Marrow Transplant With or Without G-CSF in Treating Young Patients With Hematologic Cancer or Other Diseases
This randomized phase III trial is studying donor bone marrow transplant with or without G-CSF to compare how well they work in treating young patients with hematologic cancer or other diseases.
- Conditions
- Childhood Acute Lymphoblastic Leukemia in Remission, Childhood Acute Myeloid Leukemia in Remission, Childhood Chronic Myelogenous Leukemia, Childhood Myelodysplastic Syndromes
- Trial name
- NCT00450450
- Testing
- allogeneic bone marrow transplantation, laboratory biomarker analysis, filgrastim
- Where
- 21 sites in United States
- Volunteers
- 27 people
- Sponsor
- Children's Oncology Group
Hematologic Malignancy, Stem Cell Transplant Complications
Beijing Protocol in Patients Receiving More Than 5/10 HLA-mismatched Allo-HSCT
The aim of the study is to evaluate the efficacy and safety of Beijing protocol in malignant haematologic disease patients receiving more than 5/10 HLA-mismatched allo-HSCT.
- Trial name
- NCT05921318
- Testing
- Beijing protocol
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Peking University People's Hospital
Hematological Malignancies
Study of IV CBL0137 in Previously Treated Hematological Subjects
This clinical trial is a Phase 1, open-label, sequential-group, dose-escalation (Part 1) and cohort-expansion study (Part 2) evaluating the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of intravenously (IV)…
- Trial name
- NCT02931110
- Testing
- CBL0137
- Where
- 4 sites in United States
- Volunteers
- 5 people
- Sponsor
- Incuron
Hematological Malignancies B
Biodistribution, Dosimetry, and Safety of 68Ga-EV203 in Hematological Malignancies
The goal of this clinical trial is to evaluate the biodistribution, radiation dosimetry, safety, and time-dependent image quality of ^68^Ga-EV203 injection in patients with hematological malignancies (multiple myeloma…
- Trial name
- NCT07670949
- Testing
- 68Ga-EV203 PET/CT
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Zhejiang Cancer Hospital
Hematological Malignancy, Acute Leukemia in Remission
VPA Expanded UCB Transplantation for Treatment of Patients With Hematological Malignancies
In this Phase I study, the study team will evaluate the safety of Valproic Acid (VPA) expanded cord blood stem cells defined by the lack of serious infusion reactions or graft failure in patients with hematological malignancies…
- Conditions
- Hematological Malignancy, Acute Leukemia in Remission, Acute Lymphoblastic Leukemia in Remission, Myelodysplastic Syndromes
- Trial name
- NCT03885947
- Testing
- Cord blood stem cells, Valproic Acid, Fludarabine
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Alla Keyzner
Polycythemia Vera
Safety Evaluation Study for Patients With Polycythemia Vera
This is PhaseI Dose-Escalation Study to Evaluate the Safety and Pharmacokinetics of PPMX-T003 in Polycythemia Vera
- Trial name
- NCT05074550
- Testing
- PPMX-T003
- Where
- 3 sites in Japan
- Volunteers
- 6 people
- Sponsor
- Perseus Proteomics Inc.
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Testing Binimetinib as a Potential Targeted Treatment in Cancers With NRAS Genetic Changes (MATCH-Subprotocol Z1A)
This phase II MATCH treatment trial investigates the good and bad effects of binimetinib in patients whose cancer has a genetic change called NRAS mutation.
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma
- Trial name
- NCT04439344
- Testing
- Binimetinib
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- National Cancer Institute (NCI)
Multiple Myeloma, Primary Plasma Cell Leukemia
Anti-GPRC5D CAR-T Cells (CT071) in Participants With RRMM or RRpPCL
A Phase 1/2 Open label, multicenter, clinical trial of autologous CAR T-cell therapy targeting GPRC5D, in participants with relapsed/refractory multiple myeloma or relapsed/refractory primary plasma cell leukemia.
- Trial name
- NCT06333509
- Testing
- CT071
- Volunteers
- 166 people
- Sponsor
- CARsgen Therapeutics Co., Ltd.
Hematological Malignancy, Atrial Fibrillation
Is Ibrutinib-related Atrial Fibrillation Dose Dependent
Ibrutinib, an oral inhibitor of Bruton tyrosine kinase (BTK), has recently revolutionized the treatment of various chronic B-cell malignancies and particularly chronic lymphocytic leukemia (CLL).
- Trial name
- NCT06224452
- Testing
- ibrutinib exposure
- Where
- France
- Volunteers
- 18,000 people
- Sponsor
- University Hospital, Caen
Anemia, Hematopoietic/Lymphoid Cancer
Donor Stem Cell Boost in Treating Patients With Low Blood Cells After Donor Stem Cell Transplant
This clinical trial studies how well donor stem cell boost works in treating patients with low blood cells after donor stem cell transplant.
- Conditions
- Anemia, Hematopoietic/Lymphoid Cancer, Lymphopenia, Neutropenia
- Trial name
- NCT01660347
- Testing
- Allogeneic hematopoietic stem cell transplantation, Peripheral blood stem cell transplantation, Management of therapy complications
- Volunteers
- healthy volunteers welcome
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Hematological Malignancies
Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) for the Treatment of Hematological Malignancies
Defects in the apoptotic process can lead to the onset of cancer by allowing cells to grow unchecked when an oncogneic signal is present.
- Trial name
- NCT00438178
- Testing
- Obatoclax mesylate (GX15-070MS)
- Where
- 3 sites in United States, Canada
- Volunteers
- 44 people
- Sponsor
- Gemin X
Acute Lymphoblastic Leukemia, Leukemia, Acute Myeloid (AML), Child
Study of Gene Modified Donor T-cells Following TCR Alpha Beta Positive Depleted Stem Cell Transplant
This study will evaluate pediatric patients with malignant or non-malignant blood cell disorders who are having a blood stem cell transplant depleted of T cell receptor (TCR) alfa and beta cells that comes from a partially…
- Conditions
- Acute Lymphoblastic Leukemia, Leukemia, Acute Myeloid (AML), Child, Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes
- Trial name
- NCT03301168
- Testing
- BPX-501 T cells, Rimiducid
- Where
- 10 sites in United States
- Volunteers
- 120 people
- Sponsor
- Bellicum Pharmaceuticals
Hematologic Malignancies
Bortezomib Plus Tacrolimus and Methotrexate to Prevent Graft Versus Host Disease (GVHD) After Mismatched Allogeneic Non-Myeloablative Blood Stem Cell Transplantation
The purpose of this study is to determine if Velcade (also known as bortezomib) can help prevent graft versus host disease (GVHD) developing after transplantation.
- Trial name
- NCT00369226
- Testing
- Bortezomib (Velcade), Tacrolimus, Methotrexate
- Where
- 2 sites in United States
- Volunteers
- 45 people
- Sponsor
- Dana-Farber Cancer Institute
Chronic Myeloproliferative Disorders, Leukemia
NMA Allogeneic Hematopoietic Cell Transplant in Hematologic Cancer/Disorders
RATIONALE: Giving low doses of chemotherapy before a donor peripheral blood stem cell transplant helps stop the growth of cancer cells. It also stops the patient's immune system from rejecting the donor's stem cells.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00053989
- Testing
- anti-thymocyte globulin, graft-versus-tumor induction therapy, sargramostim
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Roswell Park Cancer Institute
Hemopathy
Real-life Management of Patients Eligible for CAR-T Cell Therapy
Adoptive immunotherapy using CAR-T cells is now one of the Advanced Therapy Medicines routinely used for relapsed or refractory lymphoid hemopathies.
- Trial name
- CARAVAGE (NCT06369389)
- Testing
- Patients eligible for CAR-T treatment
- Where
- France
- Volunteers
- 550 people
- Sponsor
- University Hospital, Toulouse
Hematological Malignancies, Cancer
Cologne Cohort of Neutropenic Patients (CoCoNut)
The Cologne Cohort of Neutropenic Patients (CoCoNut) is a non-interventional cohort study assessing risk factors, interventions, and outcome of immunosuppressed patients with or without opportunistic infections.
- Conditions
- Hematological Malignancies, Cancer, Chemotherapy, Neutropenia
- Trial name
- CoCoNut (NCT01821456)
- Testing
- Antiinfectives
- Where
- Germany
- Volunteers
- 100,000 people, healthy volunteers welcome
- Sponsor
- University Hospital of Cologne
Hematologic Malignancy, Muscle Weakness
Effects of NMES and Exercise in Hematological Cancer
Physical activity levels of adult hematologic cancer patients are deficient. The resulting physical inactivity causes fatigue, muscle loss, and deterioration in physical performance values.
- Trial name
- NCT04755465
- Testing
- Neuromuscular Electrical Stimulation, Structured Exercise
- Where
- Turkey (Türkiye)
- Volunteers
- 31 people
- Sponsor
- Acibadem University
Hematologic Malignancy
Study of Posaconazole Prophylaxis in Patients Receiving Hematopoietic Stem Cell Allograft (Allo-HSC) at High Risk of Invasive Fungal Infection (IFI)
Patients receiving an allogeneic hematopoietic stem cell transplant (allo-CSH) are at high risk of infection, particularly of fungal origin.
- Trial name
- POSALLO (NCT06541067)
- Testing
- Posaconazole
- Where
- France
- Volunteers
- 30 people
- Sponsor
- Nantes University Hospital
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Impact of Aminoglycosides in Hypotensive Septic Oncology Patients
This study evaluates the impact of aminoglycosides in hypotensive septic oncologic patients. In the oncologic patient population, sepsis is a major health concern due to high mortality rates and healthcare costs.
- Conditions
- Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Septicemia
- Trial name
- NCT05045963
- Testing
- Electronic Health Record Review
- Where
- United States
- Volunteers
- 232 people
- Sponsor
- M.D. Anderson Cancer Center
Unspecified Adult Solid Tumor, Protocol Specific
Ifosfamide and Topotecan in Treating Patients With Refractory Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00003198
- Testing
- ifosfamide, topotecan hydrochloride
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.